Carcinosarcoma

Slide 1 · Carcinosarcoma

Uterine corpus

Morphology • Clonality • Prognostic interpretation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Recognize malignant epithelial and mesenchymal components in the same uterine tumor.

Relate the molecular evidence for clonality to the current carcinoma-oriented model.

Differentiate carcinosarcoma from adenosarcoma, leiomyosarcoma and other high-grade malignancies.

Interpret invasion, stage and heterologous differentiation as prognostic information.

Slide 3 · Carcinosarcoma is a biphasic malignant tumor

Malignant epithelial component

Malignant mesenchymal component

Usually adenocarcinomatous

Often high grade

Sarcomatous differentiation

Homologous or heterologous

Both elements are malignant: The biphasic appearance is the defining feature.

Slide 4 · The two components are parts of one tumor

Malignant founding clone

Divergent epithelial / mesenchymal differentiation

Biphasic carcinosarcoma

Shared molecular drivers support common ancestry rather than two unrelated adjacent neoplasms.

Slide 5 · Place of origin and clinical context

The presentation addresses carcinosarcoma of the uterine corpus.

It is discussed alongside aggressive endometrial carcinomas.

Both primary morphology and metastatic distribution link it to the carcinoma family.

Slide 6 · Historical terminology versus current concept

Historical designation

Biologic interpretation

Malignant mixed Müllerian tumor

Emphasized morphologic duality

Metaplastic / biphasic carcinoma concept

Supported by shared driver alterations

The historical name remains familiar; The contemporary model emphasizes epithelial lineage.

Slide 7 · A postmenopausal presentation prompts evaluation

Postmenopausal patient

Abnormal uterine bleeding

Tissue assessment

Bleeding is a reported typical presentation, not a disease-specific diagnostic sign.

Slide 8 · Bleeding is a symptom, not a histologic diagnosis

Carcinosarcoma commonly presents with uterine bleeding.

Other endometrial lesions may present in the same way.

The diagnosis requires tissue demonstrating appropriate malignant components.

Slide 9 · Gross appearance: A bulky uterine mass

Endometrial-cavity mass

Bulky, often polypoid growth

Possible extension toward cervical os

Shape and site raise suspicion; Gross appearance alone cannot determine the biphasic histology.

Slide 10 · The cavity–myometrium interface matters

Endometrium / cavity interface

Myometrium

Outer uterine wall

Invasion is evaluated across the wall—not inferred from tumor size alone.

Schematic—not to anatomic scale

Slide 11 · Polypoid growth can become clinically visible

The tumor may project into the cavity as a polypoid lesion.

Some tumors protrude through the cervical os.

A polypoid configuration does not imply benign biology.

Slide 12 · What must be recognized microscopically?

Carcinomatous tissue

Sarcomatous tissue

Overt malignant epithelial cytology

Glandular, papillary or solid patterns

Overt malignant mesenchymal morphology

Spindle, pleomorphic or differentiated sarcoma

Morphology drives diagnosis; Immunostains are adjuncts.

Slide 13 · Epithelial component: Common patterns

Poorly differentiated endometrioid

Serous-like carcinoma

Endometrioid gland-forming lineage

May be high-grade / poorly formed

High-grade serous phenotype

Cytologically malignant epithelium

These are examples, not two mandatory coexisting epithelial subtypes.

Slide 14 · Clear cell–type epithelium can also occur

Clear cell carcinoma among possible epithelial areas.

The histologic carcinoma component may be heterogeneous.

Recognition of carcinoma does not remove the need to search for sarcoma.

Slide 15 · An epithelial pattern may dominate a section

A section may show mostly adenocarcinoma.

The biphasic component can be focal or separated spatially.

Broader sampling may change a provisional high-grade carcinoma diagnosis.

Slide 16 · Sarcomatous component: Two broad categories

Homologous

Heterologous

Differentiation resembling uterine mesenchymal tissues

Examples: Stromal sarcoma, leiomyosarcoma-like

Differentiation resembling tissues not native to the uterus

Examples: Rhabdomyosarcoma, chondrosarcoma

This distinction refers to tissue differentiation—not to clonal independence.

Slide 17 · Homologous mesenchymal differentiation

Can resemble malignant endometrial stroma.

Can resemble a malignant smooth-muscle tumor.

The adjacent carcinomatous component establishes carcinosarcoma.

Slide 18 · Heterologous differentiation is an adverse feature

The sarcomatous component may recapitulate nonuterine tissue types.

Heterologous components with poorer prognosis.

This information supplements—not replaces—stage and invasion assessment.

Slide 19 · Rhabdomyosarcomatous differentiation

Morphologic identity

Diagnostic inference

Malignant cells with skeletal-muscle lineage

A heterologous sarcomatous form

Demonstrate bona fide rhabdomyoblastic differentiation

Confirm the accompanying carcinoma

Myogenin/MyoD1 may support rhabdomyoblastic differentiation when required.

Slide 20 · Chondrosarcomatous differentiation

Morphologic identity

Diagnostic inference

Malignant cartilage-forming component

Example of heterologous tissue

Examine cytologic malignancy within chondroid areas

Distinguish true sarcoma from incidental cartilage

Carcinoma plus malignant chondroid differentiation supports carcinosarcoma.

Slide 21 · Other heterologous components described

Malignant differentiation that resembles adipose tissue or bone.

Identity of a heterologous component requires more than a tissue-like appearance.

Careful morphologic interpretation is essential before assigning lineage.

Slide 22 · Two components may be intimately admixed

Carcinoma-rich

Sarcoma-rich

Original component-distribution schematic: Intermixed gray and blue regions, not a histologic specimen.

Component-distribution schematic (not histology)

Slide 23 · Two components may be spatially distinct

Carcinoma-rich

Sarcoma-rich

A single sampled block may capture only one region of a heterogeneous tumor.

Component-distribution schematic (not histology)

Slide 24 · Sampling can uncover otherwise missed differentiation

Resection / gross tumor

Multiple representative regions

Epithelial + sarcomatous tissue

Tumor is heterogeneous

Biopsy samples only part

Additional tissue may reveal second component

Practical inference from source-described spatial heterogeneity; No numerical block requirement implied.

Slide 25 · A limited biopsy may underrepresent a component

Carcinoma-only tissue cannot demonstrate the sarcomatous component.

Sarcoma-only tissue may obscure the epithelial lineage.

If clinically suspected, consider the sampling limitation in the pathology interpretation.

Slide 26 · Metastases typically favor the epithelial component

Biphasic uterine primary

Dissemination

Metastasis showing carcinoma

Metastatic deposits usually contain only the epithelial component.

Slide 27 · An epithelial-only metastasis is not contradictory

The metastatic site need not reproduce the biphasic primary appearance.

An epithelial-only nodal deposit can originate from a uterine carcinosarcoma.

Primary tumor morphology and clinical linkage remain essential.

Slide 28 · Shared drivers support monoclonality

Common cancer-cell ancestor

Shared driver mutations

Differing terminal morphology

Clonal origin is supported by genetics; The precise differentiation mechanism is unresolved.

Slide 29 · PTEN is one illustrative shared driver

PTEN among altered genes found in carcinosarcoma.

PTEN also features in endometrial carcinoma pathogenesis.

Its presence is evidence of molecular overlap, not a specific stand-alone diagnostic test.

Slide 30 · PIK3CA links the tumor to carcinoma biology

PIK3CA is another gene highlighted in the source.

Its alteration overlaps with the genetic landscape of endometrial carcinoma.

A listed driver gene is not present in every individual tumor.

Slide 31 · TP53 provides a major molecular connection

TP53 alterations are common in aggressive endometrial carcinomas.

Most carcinosarcomas fall in a copy-number-high/TP53-mutated molecular group.

Do not assume TP53 abnormality in every carcinosarcoma.

Slide 32 · Genetic resemblance is asymmetrical

Carcinoma-associated alterations

Typical sarcoma-associated alterations

PTEN, TP53, PIK3CA listed by Robbins

Shared across tumor components

Absence of changes typical of sarcomas

Supports carcinoma-related evolution

This is a lineage argument, not a rule that no mesenchymal alterations can ever exist.

Slide 33 · Proposed sarcomatous conversion

Epithelial-lineage cancer cell

Changes in differentiation program

Malignant mesenchymal phenotype

Conceptual model; Specific conversion mechanism remains unproven.

Slide 34 · Epigenetic regulation is a hypothesis

Robbins suggests abnormal epigenetic regulation may contribute.

The molecular steps behind sarcomatous transformation are currently uncertain.

Avoid presenting a single pathway as fully established.

Slide 35 · Clonality and conversion answer different questions

Clonality

Conversion mechanism

Do components share a founding cancer clone?

Source evidence: Shared driver mutations

How does a carcinoma-derived clone acquire sarcomatous identity?

Specific regulatory steps remain unclear

Strong support for shared origin does not establish each mechanistic step.

Slide 36 · Most carcinosarcomas map to copy-number-high disease

The copy-number-high/TP53-mutated molecular subtype.

This places most cases close to aggressive endometrial carcinoma biology.

A molecular-class label should not replace full morphologic diagnosis.

Slide 37 · Molecular groups: Where does carcinosarcoma fit?

Molecular group

Robbins context

POLE-ultramutated

Endometrial carcinoma class; Not the typical UCS pattern

MMR-deficient/MSI

Endometrial carcinoma class; Not the predominant UCS group

Copy-number low / NSMP

Often associated with endometrioid carcinoma

Copy-number high / TP53

Dominant group described for carcinosarcoma

Slide 38 · Invasion carries direct prognostic information

Depth of invasion is a principal prognostic factor.

Report whether the tumor infiltrates the myometrium.

Gross appearance alone cannot reliably establish microscopic invasion depth.

Slide 39 · Depth of myometrial invasion: Schematic

Confined to endometrium

Endometrium

Myometrium

Outer wall

Invades myometrium

Endometrium

Myometrium

Outer wall

Extends past outer wall

Endometrium

Myometrium

Outer wall

Conceptual growth-depth illustration; Not a staging substitute.

Slide 40 · Anatomic stage is a leading determinant of outcome

Stage summarizes local extension and spread beyond the uterus.

Stage, along with depth, as central prognostic determinants.

Discuss stage with the specific staging-system year.

Slide 41 · Heterologous component: A separate risk variable

Major drivers

Additional adverse finding

Disease stage

Depth of invasion

Heterologous sarcomatous differentiation

Associated with worse outcome

Histologic differentiation is not an alternative to staging.

Slide 42 · Interpreting the reported high-stage survival

An overall 5-year survival of 25–30% for high-stage disease.

This estimate applies to the referenced high-stage group, not every case.

Population outcomes must not be used to predict one individual’s course.

Slide 43 · From gross tumor to risk assessment

Confirm carcinosarcoma

Establish depth / spread

Document heterologous differentiation

Full risk interpretation depends on anatomic stage and the relevant multidisciplinary context.

Slide 44 · Important uterine biphasic differential

Feature

Carcinosarcoma

Adenosarcoma

Glandular epithelium

Malignant

Usually benign

Stromal compartment

Malignant sarcoma

Malignant stroma

Usual teaching clue

Two overtly malignant components

Benign glands with malignant stroma

Polypoid uterine lesion

Possible

Possible

Slide 45 · Malignancy of the epithelium is discriminating

Adenosarcoma has benign but architecturally abnormal glands.

Carcinosarcoma contains an overtly malignant epithelial component.

Evaluate both cytologic atypia and tissue architecture; Not merely gland presence.

Slide 46 · Contrast with pure leiomyosarcoma

Finding

Carcinosarcoma

Leiomyosarcoma

Epithelial carcinoma

Required

Not a constituent component

Mesenchymal tumor

Part of biphasic cancer

Primary smooth-muscle malignancy

Clonal model

Carcinoma-related shared drivers

Distinct uterine muscle-tumor category

Diagnostic focus

Document both malignant components

Smooth-muscle malignant criteria

Slide 47 · Contrast with endometrial stromal sarcoma

Finding

Carcinosarcoma

Endometrial stromal sarcoma

Malignant epithelial element

Present

Not defining

Genetic framing

Carcinoma-like drivers

Fusion-associated subtypes described

Pathologic classification

Biphasic tumor

Pure stromal neoplasm

Pitfall

Sarcoma-rich biopsy

Missing carcinoma if poorly sampled

Slide 48 · High-grade carcinoma can mimic a biphasic tumor

A high-grade carcinoma can show a spindle-cell or undifferentiated area.

Diagnosis rests on demonstrating a genuine malignant mesenchymal component.

Immunostains can support interpretation but do not replace morphology.

Slide 49 · Diagnostic matrix: Inspect both compartments

Diagnosis

Epithelium

Mesenchyme

Carcinosarcoma

Malignant

Malignant

Adenosarcoma

Benign (usually)

Malignant

Pure uterine sarcoma

Not malignant component

Malignant

Slide 50 · Immunohistochemistry: Use as an adjunct

Broad-spectrum cytokeratins can help identify carcinomatous elements.

Expression may overlap; Staining patterns alone are not absolutely specific.

Demonstration of both malignant morphologies remains the diagnostic anchor.

Slide 51 · Markers for a specific heterologous component

Myogenin or MyoD1 can support rhabdomyoblastic differentiation.

Select lineage-specific studies for a defined morphologic question.

Do not label all sarcomatous components “rhabdomyosarcoma” from nonspecific staining.

Slide 52 · A practical tissue-based diagnostic sequence

Assess malignant epithelium

Assess malignant mesenchyme

Correlate + sample widely

Classify and report

A conceptual workflow synthesized and specialist differential-diagnosis sources.

Slide 53 · FIGO 2023 explicitly treats carcinosarcoma as aggressive

In the 2023 FIGO endometrial system, carcinosarcoma is an aggressive histologic type.

The same anatomic extent can receive a different substage from low-grade endometrioid carcinoma.

Do not assign 2023 substages using an older simplified stage table.

Slide 54 · FIGO 2023: Stage IC concept

Histologic requirement

Anatomic requirement

Aggressive histologic type

Includes carcinosarcoma

Confined to a polyp or the endometrium

No myometrial invasion

Stage IC applies in this specified 2023 histology/anatomy scenario; Molecular modifiers may alter final stage.

Slide 55 · FIGO 2023: Stage IIC concept

Histologic requirement

Anatomic requirement

Aggressive histologic type

Includes carcinosarcoma

Any myometrial invasion

Without findings requiring higher stage

Any myometrial invasion places an aggressive histotype in IIC in the morphology-based 2023 scheme.

Slide 56 · Beyond the uterus: Regional and distant spread

FIGO stage III covers local or regional extension beyond the uterus.

FIGO stage IV includes advanced mucosal, extrapelvic peritoneal, or distant spread.

Lymph-node and extrauterine-site findings require specific documentation.

Slide 57 · 2023 FIGO molecular modifiers need attention

The 2023 staging framework encourages molecular characterization.

Certain early-stage tumors can be upstaged or downstaged by molecular subtype.

Avoid treating TP53 immunostaining alone as a complete molecular classification.

Slide 58 · Case 1: A polypoid tumor with mixed malignancy

Teaching vignette (fictional)

Postmenopausal bleeding.

Hysterectomy shows a bulky endometrial polypoid tumor.

Microscopy shows overtly malignant glands and malignant spindle-cell areas.

Which two morphologic components establish the core diagnosis?

Slide 59 · Case 1: Establish the biphasic diagnosis

Interpretation

Carcinomatous epithelium: Malignant gland-forming component.

Sarcomatous mesenchyme: Malignant spindle-cell component.

The combination supports uterine carcinosarcoma.

The polypoid configuration does not make the lesion a benign polyp.

Slide 60 · Case 2: Benign glands with malignant stroma

Teaching vignette (fictional)

Large endometrial polypoid mass.

Glands appear benign despite distorted architecture.

Intervening stroma is malignant.

Which biphasic tumor is favored over carcinosarcoma?

Slide 61 · Case 2: Favor adenosarcoma

Interpretation

Adenosarcoma: Benign epithelial glands with malignant stroma.

Carcinosarcoma requires a malignant epithelial component.

Review extensive sampling if any high-grade carcinoma appears elsewhere.

Distinguish gland presence from gland malignancy.

Slide 62 · Case 3: An epithelial-only nodal metastasis

Teaching vignette (fictional)

Uterine tumor is biphasic.

Regional node contains only morphologically malignant epithelium.

No sarcomatous component is identified in that node.

Does this contradict the uterine carcinosarcoma diagnosis?

Slide 63 · Case 3: Metastasis may contain carcinoma alone

Interpretation

No. Epithelial-only metastatic deposits as usual.

A metastatic site need not mirror primary biphasic composition.

Correlate with the fully characterized uterine primary.

Epithelial-only metastatic pattern is compatible with carcinosarcoma.

Slide 64 · Case 4: Re-evaluate staging assumptions

Teaching vignette (fictional)

Confirmed uterine carcinosarcoma.

Tumor invades the myometrium; No extrauterine extension reported.

Molecular classification is not yet available.

What is the morphology-based FIGO 2023 stage designation?

Slide 65 · Case 4: FIGO 2023 and invasion

Interpretation

Carcinosarcoma is designated an aggressive histologic type.

Any myometrial invasion falls under stage IIC in the morphology-based 2023 system.

Record molecular testing and any additional sites before finalizing staging.

This differs from simplified historical Stage I terminology.

Slide 66 · Minimum information for a useful pathology report

Identify both malignant components and specify heterologous elements if present.

Document myometrial invasion and any extrauterine or nodal tumor.

Integrate the appropriate FIGO staging framework with available molecular data.

State limitations if only a small sample is examined.

Slide 67 · Synthesis: Morphology → lineage → prognosis

Biphasic morphology

Shared carcinoma-like molecular biology

Invasion and stage govern outcome

Heterologous differentiation adds adverse prognostic information in the source.

Slide 68 · Five high-value distinctions

Carcinosarcoma has two malignant components, unlike adenosarcoma.

Its paired components share driver mutations, supporting a single founder clone.

Sarcomatous transformation mechanism remains incompletely explained.

Metastatic deposits may show only carcinoma.

Stage/depth dominate prognosis; Heterologous elements confer added risk.

Slide 69 · Primary sources and supplementary verification

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th ed. (2026), Chapter 22, pp. 915–922.

Berek JS et al. FIGO staging of endometrial cancer: 2023. J Gynecol Oncol. 2023;34:e85.

McCluggage WG. A practical approach to the diagnosis of mixed epithelial and mesenchymal tumours of the uterus. Mod Pathol. 2016;29:S78–S91.

High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations (2018).